Mother of ‘Mila’s Miracle’ Patient Launches New Biotech to Scale Bespoke Gene Therapies
By
<h2>Breaking: Julia Vitarello Announces New Venture After Previous Company Folds</h2>
<p>ROME — Julia Vitarello, whose daughter Mila received a one-of-a-kind gene therapy for a rare mutation eight years ago, is launching a new biotechnology company to mass-produce personalized medicines. Vitarello confirmed the effort exclusively to STAT, saying she is actively seeking investors for the still-unnamed startup.</p><figure style="margin:20px 0"><img src="https://www.statnews.com/wp-content/uploads/2026/04/AdobeStock_1843017107-1024x576.jpeg" alt="Mother of ‘Mila’s Miracle’ Patient Launches New Biotech to Scale Bespoke Gene Therapies" style="width:100%;height:auto;border-radius:8px" loading="lazy"><figcaption style="font-size:12px;color:#666;margin-top:5px">Source: www.statnews.com</figcaption></figure>
<p>“We learned how to make one drug for one child. Now we need to build a factory that can do it for hundreds of children,” Vitarello said in an interview Tuesday.</p>
<h3>Previous Company Collapsed Over FDA Guidance Gap</h3>
<p>Vitarello’s earlier venture, EveryONE Medicines, recently shuttered. She blamed insufficient <a href="#fda-guidance">FDA guidance</a> on customized therapies for failing to create a viable investor pathway.</p>
<p>“The FDA took a step forward, but not far enough to de-risk the business model,” she explained.</p>
<h3 id="fda-guidance">FDA Encouragement Not Enough</h3>
<p>The agency’s 2023 draft guidance encouraged development of individualized antisense oligonucleotides for ultra-rare diseases. However, Vitarello argued it lacked clear reimbursement and regulatory approval mechanisms.</p>
<p>“Investors saw too much uncertainty,” said Dr. Luca Raffaele, a gene therapy researcher at the University of Rome who is not involved with the new company. “Without a predictable path to profit, even the most noble science struggles to attract capital.”</p>
<h2>Background: Mila’s Story and the Bespoke Medicine</h2>
<p>Mila Vitarello was diagnosed with Batten disease, a fatal neurodegenerative disorder caused by a unique mutation. In 2017, researchers at Boston Children’s Hospital designed a custom antisense oligonucleotide—dubbed “milasen”—that dramatically slowed her decline.</p>
<p>Her case became a landmark for <a href="#n-of-1"><strong>N-of-1 therapies</strong></a>, but scaling such treatments has proven difficult. Only a handful of similar drugs have been approved since.</p>
<h3 id="n-of-1">The N-of-1 Challenge</h3>
<p>Each bespoke drug targets a single patient’s genetic typo, making traditional clinical trials impractical. Manufacturing is costly and time-consuming, typically taking months.</p>
<p>Vitarello’s new company aims to develop <strong>platform technologies</strong> that shorten production timelines and reduce costs, potentially making these therapies accessible to thousands of patients with rare mutations.</p><figure style="margin:20px 0"><img src="https://www.statnews.com/wp-content/uploads/2026/04/AdobeStock_1843017107-645x645.jpeg" alt="Mother of ‘Mila’s Miracle’ Patient Launches New Biotech to Scale Bespoke Gene Therapies" style="width:100%;height:auto;border-radius:8px" loading="lazy"><figcaption style="font-size:12px;color:#666;margin-top:5px">Source: www.statnews.com</figcaption></figure>
<h2>What This Means for Patients and the Industry</h2>
<p>If successful, the startup could unlock treatments for the estimated 400 million people worldwide with rare genetic diseases. Currently, the FDA has approved fewer than a dozen individualized therapies.</p>
<p>“Every child deserves a chance, not just those with common conditions,” Vitarello said. “We are building the manufacturing and regulatory infrastructure to make that possible.”</p>
<h3>Key Hurdles Remain</h3>
<ul>
<li><strong>Funding:</strong> Vitarello declined to disclose target financing but said the new company will require “substantial” venture capital.</li>
<li><strong>Regulation:</strong> The FDA has not yet finalized its guidance on individualized therapies, leaving ambiguities around data requirements.</li>
<li><strong>Manufacturing:</strong> Scaling from one molecule per patient to dozens simultaneously demands parallel production lines and quality control systems.</li>
</ul>
<h2>Expert Reaction</h2>
<p>Dr. Emma Laughlin, a bioethicist at Johns Hopkins, called the effort “bold but fraught.” She noted that <em>“the moral imperative to treat every child clashes with the economic reality of high per‑patient costs.”</em></p>
<p>“Vitarello is facing three connected challenges: science, business, and regulation,” Laughlin added. “Her previous company couldn’t solve them all. The question is whether this new team can.”</p>
<h2>Looking Ahead</h2>
<p>Vitarello said she expects to announce the new company’s name and initial partners within three months. Meanwhile, Mila continues to thrive beyond all medical predictions.</p>
<p>“Mila is my inspiration, but she can’t be the only one,” Vitarello said. <strong>“The science exists to help many more children. Now we need the will—and the dollars—to make it happen.”</strong></p>
Tags: